Teduglutide

CAS 197922-42-2

Teduglutide is based on GLP-2, an intestinal signaling peptide distinct from GLP-1. Its second residue is glycine instead of the alanine found in the native signal. A small change in the side chain makes the peptide less susceptible to cleavage by an enzyme that recognizes its amino end. That chemical explanation is only one level of the story. A clinical trial asked whether the evaluated treatment changed the need for parenteral support in patients with short bowel syndrome and intestinal failure. Investigators reported a reduction in support needs under the study conditions. Enzyme resistance alone could not establish that result. The example connects a precise sequence change with a separately tested clinical outcome, without confusing the peptide's structure with the complete treatment.